...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta oncologica. >Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel
【24h】

Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel

机译：预处理中性粒细胞与淋巴细胞比例在抗阉割前列腺癌患者中的预处理中性粒细胞比率的预后影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The neutrophil-to-lymphocyte ratio (NLR), a measure of systemic inflammatory response, has been associated with poor outcome in several solid tumors, including prostate cancer. We retrospectively investigated the prognostic role of pretreatment NLR in metastatic castration-resistant prostate cancer (mCRPC) patients treated with first-line docetaxel.Methods: All CRPC patients treated with first-line docetaxel at two Italian institutions, with available data about baseline neutrophil and lymphocyte values, were included in this retrospective analysis. Patients were divided in two groups according to NLR ratio (low NLR:3; high NLR:3). Outcome measures were progression-free (PFS) and overall survival (OS), measured from the start of docetaxel treatment. Univariate and multivariate analysis (adjusting for baseline prostate-specific antigen, alkaline phosphatase, lactate dehydrogenase, hemoglobin, albumin, performance status, use of opioids and presence of visceral disease) were performed.Results: One hundred and seventy-nine patients treated between 2004 and 2016 were analyzed and 110 had information about pretreatment NLR. Forty-six patients (42%) had low NLR and 64 (58%) had high NLR. Median PFS was 8.8 months in patients with low NLR versus 7.3 months in those with high NLR [hazard ratio (HR) 1.12, 95% confidence interval (CI) 0.75-1.69, p=.58]. Median OS was 34.9 months in patients with low NLR versus 20.2 months in those with high NLR (HR 1.85, 95% CI 1.07-3.19, p=.02). At multivariate analysis, NLR confirmed an independent impact on OS (HR 3.16, 95% CI 1.50-6.65, p=.002).Conclusion: In this retrospective series, metastatic CRPC patients who started first-line docetaxel with a low pretreatment NLR had a significantly better survival. In addition to known prognostic factors, NLR can be useful to improve prognostic evaluation of patients in this setting.
机译：背景：中性粒细胞至淋巴细胞比（NLR），一种全身炎症反应的量度，几乎与几种实体肿瘤的结果有关，包括前列腺癌。我们回顾性地研究了预处理NLR在用第一线Docetaxel治疗的转移性阉割的前列腺癌（MCRPC）患者中的预处理NLR.methods：所有CRPC患者在两种意大利机构的第一线Docetaxel治疗，有关于基线中性粒细胞的可用数据和淋巴细胞值包括在此回顾性分析中。根据NLR比例分为两组（低NLR：3;高NLR：＆ 3）。结果措施是无进展的（PFS）和总存活（OS），从多西紫杉醇治疗开始衡量。进行单变量和多变量分析（调整基线前列腺特异性抗原，碱性磷酸酶，乳酸脱氢酶，血红蛋白，白蛋白，表现形式和内脏疾病存在的使用）。结果：2004年间治疗一百七十九岁患者分析了2016年，110人有关于预处理NLR的信息。四十六名患者（42％）具有低NLR，64（58％）具有高NLR。 NLR低NLR患者的中位数PFS为8.8个月，具有高NLR [危险比（HR）1.12,95％置信区间（CI）0.75-1.69，P = .58]。中位OS为34.9个月，低NLR对20.2个月的NLR（HR 1.85,95％CI 1.07-3.19，P = .02）。在多变量分析时，NLR确认对OS的独立影响（HR 3.16,95％CI 1.50-6.65，P = .002）。结论：在此回顾性系列中，开始具有低预处理NLR的第一线多西紫杉醇的转移性CRPC患者生存率明显更好。除了已知的预后因素外，NLR还可用于改善该环境中患者的预后评估。

著录项

  • 来源
    《Acta oncologica.》 |2017年第6期|共8页
  • 作者

    Buttigliero Consuelo; Pisano Chiara; Tucci Marcello; Vignani Francesca; Bertaglia Valentina; Iaconis Davide; Guglielmini Pamela; Numico Gianmauro; Scagliotti Giorgio V.; Di Maio Massimo;

  • 作者单位

    Univ Turin San Luigi Gonzaga Hosp Div Med Oncol Dept Oncol Reg Gonzole 10 I-10043 Turin Italy;

    Univ Turin San Luigi Gonzaga Hosp Div Med Oncol Dept Oncol Reg Gonzole 10 I-10043 Turin Italy;

    Univ Turin San Luigi Gonzaga Hosp Div Med Oncol Dept Oncol Reg Gonzole 10 I-10043 Turin Italy;

    Univ Turin San Luigi Gonzaga Hosp Div Med Oncol Dept Oncol Reg Gonzole 10 I-10043 Turin Italy;

    Univ Turin San Luigi Gonzaga Hosp Div Med Oncol Dept Oncol Reg Gonzole 10 I-10043 Turin Italy;

    Univ Turin San Luigi Gonzaga Hosp Div Med Oncol Dept Oncol Reg Gonzole 10 I-10043 Turin Italy;

    SS Antonio &

    Biagio &

    Cesare Arrigo Hosp Oncol Unit Alessandria Italy;

    SS Antonio &

    Biagio &

    Cesare Arrigo Hosp Oncol Unit Alessandria Italy;

    Univ Turin San Luigi Gonzaga Hosp Div Med Oncol Dept Oncol Reg Gonzole 10 I-10043 Turin Italy;

    Univ Turin San Luigi Gonzaga Hosp Div Med Oncol Dept Oncol Reg Gonzole 10 I-10043 Turin Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号